Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Holders of 5% or more of ENTA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Enanta Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G | 12.10%3.49M shares | New | Nov 7, 20251 filing | Nov 7, 2025 | SEC |
| Farallon Capital Partners, L.P. | 13G/A | 9.80%2.82M shares | −0.10 ppfrom 9.90% | Feb 11, 20252 filings | Feb 5, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.80%1.67M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Luly Jay R. | 13D/A | 7.70%1.70M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Deep Track Capital, LP | 13G/A | 6.78%1.96M shares | +1.45 ppfrom 5.33% | Oct 9, 20252 filings | Feb 13, 2026 | SEC |
| Krensavage Asset Management, LLC | 13G | 5.10%1.09M shares | New | Feb 27, 20241 filing | Feb 27, 2024 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Enanta Pharmaceuticals Inc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20266:06 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 13, 20268:43 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 6.78%1.96M shares | +1.45 ppfrom 5.33% | Dec 31, 2025 | SEC |
| Feb 5, 20262:48 PM ET | Farallon Capital Partners, L.P.and 28 others | 13G/A | 9.80%2.82M shares | −0.10 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Jan 20, 20264:42 PM ET | Integrated Core Strategies (US) LLCand 3 others | 13G/A | 2.30%670.4K shares | −1.80 ppfrom 4.10%Below 5% | Dec 31, 2025 | SEC |
| Nov 13, 20254:29 PM ET | Integrated Core Strategies (US) LLCand 3 others | 13G/A | 4.10%1.14M shares | −2.40 ppfrom 6.50%Below 5% | Sep 30, 2025 | SEC |
| Nov 7, 202512:10 PM ET | Janus Henderson Group PLCand 1 other | 13G | 12.10%3.49M shares | New | Oct 31, 2025 | SEC |
| Oct 9, 20254:52 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.33%1.48M shares | New | Oct 2, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.80%1.67M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20255:05 PM ET | Luly Jay R. | 13D/A | 7.70%1.70M shares | – | Feb 12, 2025 | SEC |
| Feb 11, 202512:11 PM ET | Farallon Capital Partners, L.P.and 27 others | 13G/A | 9.90%2.11M shares | – | Dec 31, 2024 | SEC |
| Jan 22, 20254:01 PM ET | Integrated Core Strategies (US) LLCand 3 others | 13G | 6.50%1.38M shares | New | Jan 14, 2025 | SEC |
| Feb 27, 20241:11 PM ET | Krensavage Asset Management, LLCand 2 others | 13G | 5.10%1.09M shares | New | Feb 22, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Enanta Pharmaceuticals Inc shares.
No Form 144 notices for Enanta Pharmaceuticals Inc are on file.